Viewing data from:

CLOMIPHENE CITRATE

ANDA

CLOMIPHENE CITRATE | A075528 | COSETTE PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 4 NDCs

Highest NADAC/Unit

$16.74

per ea

Lowest NADAC/Unit

$5.66

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00713088509CLOMID 50 MG TABLET	$16.74	EA	—	$5.66	2026-06-12
00713088530CLOMID 50 MG TABLET	$16.74	EA	—	$5.66	2026-06-12
83390010709CLOMIPHENE CITRATE 50 MG TAB	$5.66	EA	Generic	—	2026-06-17
83390010730CLOMIPHENE CITRATE 50 MG TAB	$5.66	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$109.22

Highest Price

$297.61

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00713-0885-09CLOMIPHENE CITRATE 50MG TAB	$109.22	FSS	Golden State Medical Supply, Inc.	06/14/2028
00713-0885-30CLOMIPHENE CITRATE 50MG TAB	$297.61	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain5 active DMFs4 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVCLOMIPHENE CITRATE

DMF 39571980

FIS FABBRICA ITALIANA SINTETICI SPACLOMIPHENE CITRATE

DMF 56741984

MENADIONA SLCLOMIPHENE CITRATE

DMF 75901988

PCASCLOMIPHENE CITRATE

DMF 289472015

VIYASH LIFE SCIENCES PRIVATE LTDCLOMIPHENE CITRATE USP

DMF 401112024

UNICHEM LABORATORIES LTDInactiveCLOMIPHENE CITRATE

DMF 63361985

EGIS PHARMACEUTICALS PRIVATE LTDInactiveCLOMIPHENE CITRATE USP

DMF 65681986

EGIS PHARMACEUTICALS PRIVATE LTDInactiveCLOMIPHENE CITRATE TABLETS

DMF 86721989

PCASInactiveCLOMIPHENE CITRATE

DMF 147282000

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 30, 1999	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 30, 1999

No patent or exclusivity listings for this strength.